HG381 / HitGen - LARVOL DELTA

A Study of HG381 Administered to Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=57 | Recruiting | Sponsor: HitGen Inc. | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Jun 2024 ➔ Dec 2025

Monotherapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study of HG381 Administered to Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=57 | Recruiting | Sponsor: HitGen Inc. | Trial completion date: Jun 2024 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Jun 2024

Metastases • Monotherapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study of HG381 Administered to Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=57 | Recruiting | Sponsor: HitGen Inc. | Trial completion date: Dec 2023 ➔ Jun 2024

Metastases • Monotherapy • Trial completion date • Oncology • Solid Tumor

A Study of HG381 Administered to Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=57 | Recruiting | Sponsor: HitGen Inc. | Trial completion date: Mar 2023 ➔ Dec 2023 | Trial primary completion date: Dec 2022 ➔ Dec 2023

Metastases • Monotherapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study of HG381 Administered to Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=57 | Recruiting | Sponsor: HitGen Inc. | Initiation date: Mar 2022 ➔ Oct 2021

Monotherapy • Trial initiation date • Oncology • Solid Tumor

A Study of HG381 Administered to Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=57 | Recruiting | Sponsor: HitGen Inc. | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2022 ➔ Mar 2023 | Initiation date: Sep 2021 ➔ Mar 2022 | Trial primary completion date: May 2022 ➔ Dec 2022

Enrollment open • Monotherapy • Trial completion date • Trial initiation date • Trial primary completion date • Oncology • Solid Tumor

Phase 1 Study of HG381 Administered to Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=57; Not yet recruiting; Sponsor: HitGen Inc.

New P1 trial • Oncology • Solid Tumor

HitGen’s STING agonist nails tacit trial nod in China (GBI Health) - "Chengdu-based HitGen Inc., (688222.SH) announced receipt of a clinical trial nod from the National Medical Products Administration (NMPA) to initiate a clinical study for its HG381, a second-generation, acyclic dinucleotide small-molecule STING agonist in advanced solid tumors."

Non-US regulatory • Oncology • Solid Tumor